PMID- 20198341
OWN - NLM
STAT- MEDLINE
DCOM- 20100604
LR  - 20210513
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 36
IP  - 4
DP  - 2010 Apr
TI  - Isostrychnopentamine, an indolomonoterpenic alkaloid from Strychnos usambarensis, 
      with potential anti-tumor activity against apoptosis-resistant cancer cells.
PG  - 961-5
AB  - Isostrychnopentamine (ISP) is an indolomonoter-penic alkaloid that is present in 
      the leaves of Strychnos usambarensis, an East African small tree. We have 
      reported previously pro-apoptotic effects induced in vitro by ISP in the human 
      HCT-116 colon cancer cell line, a model that displays relative sensitivity to 
      apoptosis. In the present study, we observed that the in vitro growth inhibitory 
      activities of ISP are similar in cancer cells that display sensitivity versus 
      resistance to apoptosis. We made use of the U373 glioblastoma and the A549 
      non-small cell lung cancer (NSCLC) cell lines as models relatively resistant to 
      apoptosis, and the human PC-3 prostate cancer cell line as a model relatively 
      sensitive to apoptosis. While ISP induced transient decreases in [ATP]i and 
      apoptosis in human U373 GBM cells, it did not provoke such features in A549 NSCLC 
      cells. It thus seems that ISP-induced anti-cancer activity can lead to 
      pro-apoptotic effects as a consequence, while apoptosis seems not to be the main 
      cause by which ISP induces cancer cell death. ISP is a compound that merits 
      further investigations in order to: i) identify the mechanism(s) of action by 
      which it kills cancer cells, and ii) hemisynthesize novel ISP derivatives aiming 
      to overcome, at least partly, the resistance of metastatic cancers to apoptosis.
FAU - Saidou Balde, El-Hadj
AU  - Saidou Balde el-H
AD  - Laboratoire de Toxicologie, Departement de BioAnalyse et Toxicologie 
      Pharmaceutique, Institut de Pharmacie, Universite Libre de Bruxelles, 1050 
      Brussels, Belgium.
FAU - Megalizzi, Veronique
AU  - Megalizzi V
FAU - Cao, Martine
AU  - Cao M
FAU - Angenot, Luc
AU  - Angenot L
FAU - Kiss, Robert
AU  - Kiss R
FAU - Van Damme, Marc
AU  - Van Damme M
FAU - Frederich, Michel
AU  - Frederich M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Carbolines)
RN  - 67673-13-6 (isostrychnopentamine)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
SB  - IM
EIN - Int J Oncol. 2013 Dec 09;36(5):1315-1315. PMID: 24442336
MH  - Adenosine Triphosphate/metabolism
MH  - Antineoplastic Agents, Phytogenic/isolation & purification/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Brain Neoplasms/pathology
MH  - Breast Neoplasms/pathology
MH  - Carbolines/isolation & purification/*pharmacology
MH  - Carcinoma, Non-Small-Cell Lung/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance, Neoplasm
MH  - Female
MH  - Glioblastoma/pathology
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Lung Neoplasms/pathology
MH  - Male
MH  - Neoplasms/metabolism/*pathology
MH  - Plant Leaves
MH  - Prostatic Neoplasms/pathology
MH  - *Strychnos/chemistry
MH  - Time Factors
EDAT- 2010/03/04 06:00
MHDA- 2010/06/05 06:00
CRDT- 2010/03/04 06:00
PHST- 2010/03/04 06:00 [entrez]
PHST- 2010/03/04 06:00 [pubmed]
PHST- 2010/06/05 06:00 [medline]
AID - 10.3892/ijo_00000575 [doi]
PST - ppublish
SO  - Int J Oncol. 2010 Apr;36(4):961-5. doi: 10.3892/ijo_00000575.